40 results
8-K/A
EX-99.2
NTBL
Notable Labs Ltd
29 Nov 23
Financial Statements and Exhibits
5:00pm
Ended December 31,
Federal statutory income tax
State income taxes
PPP loan forgiveness
Share-based compensation
R&D credits
ASC 740-10 reserve
SAFE … , if not utilized.
As of December 31, 2022, the Company had federal and California research and development (“R&D”) credit carryforwards of approximately
6-K
EX-99.2
NTBL
Notable Labs Ltd
2 Jun 22
Notice of Annual General Meeting of Shareholders
5:00pm
, and as a part time chair of the R&D division at the Chaim Sheba Medical Center at Tel Hashomer and as chair of its Institute Review Board. Prof. Harats
424B5
NTBL
Notable Labs Ltd
11 Feb 22
Prospectus supplement for primary offering
5:28pm
must generally fulfill certain conditions to be eligible for Preferred Technology Enterprise status including, inter alia, an R&D expenses level
6-K
EX-99.2
lh4cyzga2q
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
6-K
ijefef
16 Aug 21
Current report (foreign)
7:00am
6-K
bi0dq
11 May 21
Current report (foreign)
7:00am
424B8
4pa 4lj98lqj27
19 Apr 21
Prospectus unintentially filed late
5:06pm
424B5
zb5lt2pe2h7
12 Apr 21
Prospectus supplement for primary offering
9:07am
424B5
cqlbpq
9 Apr 21
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
v4m135 o0
6 Apr 21
VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3:33pm
424B5
edcw2plk4s 340
15 Jan 21
Prospectus supplement for primary offering
7:00am
424B3
p2v4cq1s jglo7
16 Nov 20
Prospectus supplement
7:15am
6-K
ul9gg
16 Nov 20
Current report (foreign)
7:00am
6-K
EX-99.1
40vzw
13 Oct 20
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
8:30am
6-K
EX-99.2
3sha05 xu74zo7baw
28 May 20
Notice of Annual General Meeting of Shareholders
9:14am
6-K
7xza7e 99
14 May 20
Current report (foreign)
7:25am
6-K
EX-10.1
epl3l
12 May 20
Current report (foreign)
12:04pm